Non-Viral Vector-Mediated Gene Therapy for ALS: Challenges and Future Perspectives

Area of Science:

• Neuroscience
• Genetics
• Biotechnology

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with no current cure.
• Gene therapy presents a promising avenue for developing effective ALS treatments.

Purpose of the Study:

• To review novel therapies for ALS, focusing on non-viral vector-mediated gene therapy.
• To discuss the challenges and future prospects of non-viral vectors in ALS treatment.

Main Methods:

• Review of current research and clinical stages of ALS therapies.
• Analysis of non-viral vector applications, including lipid- and polymer-based nanoparticles, cationic polymers, and exosomes.
• Discussion of delivery challenges and emerging techniques like CRISPR-Cas9 and focused ultrasound.

Main Results:

• Non-viral vectors can achieve long-term, stable gene expression in neurons with minimal immunological complications.
• Significant bottlenecks exist in systemic administration and precise control of gene delivery for ALS treatment.

Conclusions:

• Non-viral vector-delivered gene therapy holds significant potential for managing ALS.
• Advancements in gene editing, stem cells, and focused ultrasound may enhance personalized gene therapy for ALS.